For the first time, a drug targeting a protein that drives breast cancer growth has been shown to work against tumors with very low levels of the protein.
It’s not a cure. But this latest gain for targeted cancer therapy — which was reported in Chicago at the yearly meeting of the American Society of Clinical Oncology and published by the New England Journal of Medicine — could offer new treatment possibilities to thousands of patients with advanced breast cancer.
